Clinical & developmental immunology · 2012
Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kobold Sebastian, Luetkens Tim, Bartels Britta Marlen, Cao Yanran, Hildebrandt York, Sezer Orhan, Reinhard Henrike, Templin Julia, Bartels Katrin, Lajmi Nesrine, Haag Friedrich, Bokemeyer Carsten, Kröger Nicolaus, Atanackovic Djordje
Аннотация
BACKGROUND: Multiple myeloma (MM) and its therapies may induce a severely compromised humoral immunity. We have performed a longitudinal analysis of IgG-antibody responses against influenza virus (FLU) and tetanus toxoid (TT) as surrogate markers for the B cell-mediated immunity in MM patients.
METHODS: 1094 serum samples of 190 MM patients and samples from 100 healthy donors were analyzed by ELISA for FLU- and TT-specific antibodies.
RESULTS: MM patients evidenced lower levels of FLU- and TT-specific antibodies than healthy controls (P < 0.001). Immunoreactivity decreased with progressing disease and worsening clinical status. Levels of FLU- and TT-specific antibodies increased shortly (0-6 months) after alloSCT (P < 0.001), a time-period during which intravenous immunoglobulin (IVIG) is routinely applied. Thereafter, antibody concentrations declined and remained suppressed for 3 years in the case of FLU-specific and for more than 5 years in the case of TT-specific antibodies.
CONCLUSIONS: We found that MM is associated with a profound disease- and therapy-related immunosuppression, which is compensated for a few months after alloSCT, most likely by application of IVIG. This and the differences regarding the recovery of anti-FLU and anti-TT antibody titers during the following years need to be taken into account for optimizing IVIG application and immunization after alloSCT.
METHODS: 1094 serum samples of 190 MM patients and samples from 100 healthy donors were analyzed by ELISA for FLU- and TT-specific antibodies.
RESULTS: MM patients evidenced lower levels of FLU- and TT-specific antibodies than healthy controls (P < 0.001). Immunoreactivity decreased with progressing disease and worsening clinical status. Levels of FLU- and TT-specific antibodies increased shortly (0-6 months) after alloSCT (P < 0.001), a time-period during which intravenous immunoglobulin (IVIG) is routinely applied. Thereafter, antibody concentrations declined and remained suppressed for 3 years in the case of FLU-specific and for more than 5 years in the case of TT-specific antibodies.
CONCLUSIONS: We found that MM is associated with a profound disease- and therapy-related immunosuppression, which is compensated for a few months after alloSCT, most likely by application of IVIG. This and the differences regarding the recovery of anti-FLU and anti-TT antibody titers during the following years need to be taken into account for optimizing IVIG application and immunization after alloSCT.
Предметные рубрики MeSH
AgedAntibodies, BacterialAntibodies, ViralAntineoplastic AgentsB-LymphocytesCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansImmunity, HumoralImmunoglobulin GImmunoglobulins, IntravenousImmunosuppression TherapyAlphainfluenzavirusInjections, IntravenousLongitudinal StudiesMaleMiddle AgedMultiple MyelomaNucleocapsid ProteinsRNA-Binding ProteinsStem Cell TransplantationTetanus ToxoidTransplantation, HomologousViral Core Proteins